- Nature Microbiology
- +44 207 843 4889
- Nature Research Editors
- United Kingdom
About Nonia Pariente
I come from a mid-sized city on the northwestern coast of Spain. My interest in science initially took me to Madrid, where I finished university and received a PhD in molecular biology. In Madrid, I studied RNA virus evolution and new antiviral strategies with Esteban Domingo. I then moved to UCLA, where I focused on developing lentiviral vectors for gene therapy in Irvin Chen’s laboratory. In 2007, I made the plunge from bench to desk and joined the EMBO Reports editorial team as Reviews Editor, becoming Scientific Editor two years later and Senior Editor in 2012. At EMBO Reports, I was responsible for microbiology and immunology, among other areas, and spent many years expanding my understanding and love for all things microbial. In the summer of 2015, I joined the Nature Microbiology editorial launch team, handling all things related to virology and mycology (and for a brief while parasitology) and -after a couple of stints covering microbiology at Nature- I became the Chief Editor of Nature Microbiology in 2019. I look forward to interacting with the community and providing a venue to publish the most important advances in the field.
Recent Comments
Thanks Rick for this behind the scenes look at the project, which perfectly complements the Consensus Statement. Congratulations on the monster effort on a very necessary cause!
Great post Nuno! I'm always amazed by the speed and portability of the existing technology and your approach of empowering the local communities to do the analyses autonomously will make this a sta...
Thanks Ben! The Dimmock et al was also a great book - my Virology was lecture-based, sans book, but I did miss having an engaging one to hand!
Great post Mike!
Fantastic post! I enjoyed reading this and learned a lot!
Thanks David!!
Very nice post! took me back to my postdoc days in SoCal. Do you know what happened in Jan 2011? Chlorophyll levels were huge!
I think clinical trials have to be set up to prove efficacy for every intended use, although the safety and dose-escalation trials might not be necessary, I would imagine